LakeShore Biopharma Announces Receipt of Buyer Group Notice and Postponement of Extraordinary General Meeting of Shareholders

LakeShore Biopharma Co., Ltd (“LakeShore Biopharma” or the “Company”) (OTCPK: LSBCF; OTCPK: LSBWF), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced that it has received a notice, dated February 4, 2026, from legal counsel to a group (the

Delonix Bioworks Announces IND Clearance for DX-104, a Novel Engineered MenB OMV Vaccine Candidate, in China and Australia

Delonix Bioworks, a clinical-stage biotechnology company developing next-generation bacterial vaccines, recently announced that its Group B meningococcal (MenB) vaccine candidate, DX-104, has received Investigational New Drug (IND) clearance from China's National Medical Products Administration (NMPA). This follows the successful completion of Clinical Trial Notification (CTN) procedures and ethics committee approval in Australia in January 2026.

Solairus Founder and CEO Dan Drohan Recognized by Living Legends of Aviation

Recognition Reflects Company's Commitment to Operational Excellence Solairus, a leading aircraft management and charter services provider, announced that Founder and Chief Executive Officer Dan Drohan has been recognized by the Living Legends of Aviation as part of the organization's 23rd Annual Awards. The Living Legends of Aviation Awards are among the industry's most respected honors,

RARE INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Ultragenyx Pharmaceutical Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

NEW YORK CITY, NY / ACCESS Newswire / February 6, 2026 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) and certain of its officers. This lawsuit seeks to recover damages against Defendants for alleged violations of the

CRC Industries Raises $100,000 for Skilled Trade Scholarships with Sale of Hydrogen-Powered ’57 Chevrolet Bel Air at Barrett-Jackson

The company's Build for the Future initiative delivers 100% of the hammer price to TechForce Foundation CRC Industries, a global leader in specialty chemicals for automotive and industrial maintenance and repair, today announced that its hydrogen-powered 1957 Chevrolet Bel Air sold for $100,000 as a featured charity vehicle at the Barrett-Jackson Scottsdale auction on January

From Early Morning Practices to Late-Night Drives: Kruger Products Champions Canada’s Hockey Parents in New Campaign, The Kruger Big Assist “Parent Assist”

From Early Morning Practices to Late-Night Drives: Kruger Products Champions Canada's Hockey Parents in New Campaign, The Kruger Big Assist “Parent Assist” GlobeNewswire February 06, 2026 New campaign supports Kruger Products' efforts to help more kids participate in minor hockey through the Kruger Big Assist program, now in its sixth year Kruger Products announces official

Aurora Mobile’s EngageLab Partners with Blurams to Drive Global IoT Service Growth

Aurora Mobile's EngageLab Partners with Blurams to Drive Global IoT Service Growth GlobeNewswire February 06, 2026 SHENZHEN, China, Feb. 06, 2026 (GLOBE NEWSWIRE) — Aurora Mobile (NASDAQ: JG) (“Aurora Mobile” or the “Company”), a leading provider of customer engagement and marketing technology services in China, today announced that its leading AI-driven customer engagement platform, EngageLab,

Roivant Announces Positive Phase 2 Results for Brepocitinib in Cutaneous Sarcoidosis (CS) and Reports Financial Results for the Third Quarter Ended December 31, 2025

Roivant Announces Positive Phase 2 Results for Brepocitinib in Cutaneous Sarcoidosis (CS) and Reports Financial Results for the Third Quarter Ended December 31, 2025 GlobeNewswire February 06, 2026 Brepocitinib 45 mg significantly improved cutaneous sarcoidosis disease activity, achieving a 22.3-point improvement in mean CSAMI-A at Week 16 versus a 0.7-point improvement in placebo (D21.6 P<0.0001).

Immunovant Provides Corporate Updates and Reports Financial Results for the Third Quarter Ended December 31, 2025

Immunovant Provides Corporate Updates and Reports Financial Results for the Third Quarter Ended December 31, 2025 GlobeNewswire February 06, 2026 IMVT-1402 potentially registrational trial in difficult-to-treat rheumatoid arthritis (D2T RA) fully enrolled, with topline data expected in the second half of calendar year 2026; topline data from the proof-of-concept trial in cutaneous lupus erythematosus (CLE)

Scroll to Top